These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2066455)

  • 1. High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression.
    Beasley CM; Sayler ME; Bosomworth JC; Wernicke JF
    J Clin Psychopharmacol; 1991 Jun; 11(3):166-74. PubMed ID: 2066455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoxetine versus trazodone: efficacy and activating-sedating effects.
    Beasley CM; Dornseif BE; Pultz JA; Bosomworth JC; Sayler ME
    J Clin Psychiatry; 1991 Jul; 52(7):294-9. PubMed ID: 2071559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine.
    Tollefson GD; Greist JH; Jefferson JW; Heiligenstein JH; Sayler ME; Tollefson SL; Koback K
    J Clin Psychopharmacol; 1994 Dec; 14(6):385-91. PubMed ID: 7884018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
    Tollefson GD; Holman SL; Sayler ME; Potvin JH
    J Clin Psychiatry; 1994 Feb; 55(2):50-9. PubMed ID: 8077155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
    Fawcett J; Marcus RN; Anton SF; O'Brien K; Schwiderski U
    J Clin Psychiatry; 1995; 56 Suppl 6():37-42. PubMed ID: 7649972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.
    Wernicke JF; Sayler ME; Koke SC; Pearson DK; Tollefson GD
    Depress Anxiety; 1997; 6(1):31-9. PubMed ID: 9394873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoxetine: activating and sedating effects.
    Beasley CM; Potvin JH
    Int Clin Psychopharmacol; 1993; 8(4):271-5. PubMed ID: 8277147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of fluoxetine on symptoms of insomnia in depressed patients.
    Satterlee WG; Faries D
    Psychopharmacol Bull; 1995; 31(2):227-37. PubMed ID: 7491373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine: activating and sedating effects at multiple fixed doses.
    Beasley CM; Sayler ME; Weiss AM; Potvin JH
    J Clin Psychopharmacol; 1992 Oct; 12(5):328-33. PubMed ID: 1479050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder.
    Stark P; Hardison CD
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):53-8. PubMed ID: 3882682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
    Amini H; Aghayan S; Jalili SA; Akhondzadeh S; Yahyazadeh O; Pakravan-Nejad M
    J Clin Pharm Ther; 2005 Apr; 30(2):133-8. PubMed ID: 15811165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
    Fawcett J; Barkin RL
    J Clin Psychiatry; 1998 Mar; 59(3):123-7. PubMed ID: 9541155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of an acute antidepressant response to fluoxetine and sertraline.
    Flament MF; Lane RM; Zhu R; Ying Z
    Int Clin Psychopharmacol; 1999 Sep; 14(5):259-75. PubMed ID: 10529069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
    Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
    Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Major agitated-anxious versus blunted-retarded depression: differential effects of fluoxetine].
    Dalery J; Bouhassira M; Kress JP; Lancrenon S; Tafani A; Hantouche EG
    Encephale; 1995; 21(3):217-25. PubMed ID: 7649072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder.
    Cohn JB; Wilcox C
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):26-31. PubMed ID: 3882677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression.
    Beasley CM; Bosomworth JC; Wernicke JF
    Psychopharmacol Bull; 1990; 26(1):18-24. PubMed ID: 2196623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.